ArticleBMC rheumatology2021
Vitamin D supplementation in systemic lupus erythematosus: relationship to disease activity, fatigue and the interferon signature gene expression.
Article in BMC rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05430087 (The Combination of Vitamin D and Curcumin Piperine Attenuates the Disease Activity and Pro-Inflammatory Cytokines Levels in Systemic Lupus Erythematosus Patients), which is not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Combination of Vitamin D and Curcumin Piperine Attenuates the Disease Activity and Pro-Inflammatory Cytokines Levels in Systemic Lupus Erythematosus Patients
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- A Systematic Review and Meta-Analysis of the Effects of Vitamin D on Systemic Lupus Erythematosus.Nutrients · 2025Pooled it
- High- vs. routine-dose vitamin D3 in severe lupus on pulse methylprednisolone: a randomized, double-blind, placebo-controlled clinical trial.Clinical rheumatology · 2025Trial
- Randomised Clinical Trial Study: The Combination of Vitamin D and Curcumin Piperine Attenuates Disease Activity and Pro-inflammatory Cytokines Levels Insystemic Lupus Erythematosus Patients.Current rheumatology reviews · 2024Trial
- Clinical and serological association of plasma 25-hydroxyvitamin D (25(OH)D) levels in lupus and the short-term effects of oral vitamin D supplementation.Arthritis research & therapy · 2023Trial
- Article
- Serum Vitamin D Levels and Disease Activity in Systemic Lupus Erythematosus: Association with Anti-dsDNA Antibodies and Selected Lifestyle Factors.Journal of clinical medicine · 2026Article
- Vitamin D in inflammatory rheumatic diseases: still a challenge.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Review
- Combined assessment of 25(OH)D, CD4Frontiers in immunology · 2026Article
- Vitamin DFrontiers in immunology · 2026Review
- Low Vitamin D and C Levels are Associated with Increased Disease Activity in Jordanian RA and SLE Patients: A Case-Control StudyEndocrine, metabolic & immune disorders drug targets · 2026Article
- Pharmacological insights into gut microbiota modulation in systemic lupus erythematosus: Mechanisms, treatment strategies, and clinical implications.The Journal of pharmacology and experimental therapeutics · 2025Review
- Type 1 interferon signalling orchestrated by gut microbiota suppresses IgE-mediated anaphylaxis associated with vitamin D3 signalling.The World Allergy Organization journal · 2025Article
- Molecular Insight into the Role of Vitamin D in Immune-Mediated Inflammatory Diseases.International journal of molecular sciences · 2025Review
- Review
- Drug History and SLE Laboratory Findings Among Iraqi Patients: A Hospital-Based Study.Health science reports · 2025Article
- Effects of Vitamin D Supplementation on Fatigue and Disease Activity in Systemic Lupus Erythematosus.Cureus · 2025Article
- Immune metabolic restoration in systemic lupus erythematosus: the impact of gut microbiota, probiotics, and nutritional synergy.Frontiers in immunology · 2025Review
- Serum 25-Hydroxyvitamin D Levels and Disease Activity in Patients with Systemic Lupus Erythematosus: An Exploratory Study in Western Mexico.Diseases (Basel, Switzerland) · 2024Article
- Factors associated with 25-hydroxyvitamin D level in Chinese hospitalized patients with systemic lupus erythematosus: a retrospective cohort study.Rheumatology international · 2024Article
- Vitamin D in Primary Sjogren's Syndrome (pSS) and the Identification of Novel Single-Nucleotide Polymorphisms Involved in the Development of pSS-Associated Diseases.Diagnostics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn addition to the well-known role of vitamin D in calcium homeostasis and bone metabolism, vitamin D is important in the modulation of the immune system and inflammatory processes. Vitamin D deficiency is common in patients with systemic lupus erythematosus (SLE), possibly as a result of sun avoidance. The aim of this prospective open-label study was to assess the effect of the treatment of vitamin D deficiency and insufficiency in SLE patients, particularly with regards to disease activity, fatigue and interferon signature gene expression.
methods31 SLE patients, 13 with vitamin D deficiency and 18 with vitamin D insufficiency were treated with vitamin D3. They were supplemented with vitamin D3 8000 IU daily for 8 weeks if they were vitamin D deficient, or 8000 IU daily for 4 weeks if they were insufficient. This was followed by 2000 IU daily maintenance. They were assessed at baseline, after 6 and 12 months by means of an interview, filling in questionnaires and blood tests. The expression of 12 interferon signature genes in RNA extracted from whole blood was measured by using QuantiGene Plex technology.
resultsAn improvement in disease activity measured by systemic lupus erythematosus disease activity index-2K (SLEDAI-2K; p = 0.028) and fatigue measured by fatigue severity scale (FSS; p = 0.071) at 12 months were noted. A significant decrease in anti-double stranded deoxyribonucleic acid (dsDNA) titre (p = 0.045) was also noted. The mean interferon signature gene expression score decreased from baseline to 6 months, however statistical significance was not achieved (p = 0.165).
conclusionsImproved disease activity and fatigue have been noted when Vitamin D has been supplemented in vitamin D deficient/insufficient SLE patients. One possible mechanism could be the suppression of the interferon signature gene expression.
trial registrationThe study was registered with the ISRCTN registry on 12/04/2021 (Trial ID: ISRCTN59058825).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.